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Community-associated methicillin-resistant Staphylo-
coccus aureus (CA-MRSA) has become a major problem in 
US hospitals already dealing with high levels of hospital-as-
sociated MRSA (HA-MRSA). Using antimicrobial drug sus-
ceptibility data for 1999–2006 from The Surveillance Net-
work, we characterized the relationship between outpatient 
and inpatient levels of CA-MRSA nationally. In outpatients, 
the frequency of CA-MRSA isolates has increased >7× dur-
ing 1999–2006, which suggests that outpatients have be-
come a major reservoir for CA-MRSA. However, contrary to 
results in other reports, although CA-MRSA increases are 
associated with decreases in the frequency of HA-MRSA 
in hospitals, the decreases are only modest. This ﬁ  nding 
suggests that instead of replacing HA-MRSA in the hospi-
tal, CA-MRSA is adding to the overall presence of MRSA 
already found within the hospital population.
T
he past decade has seen a large increase in infections 
with hospital-associated methicillin-resistant Staphylo-
coccus aureus (HA-MRSA) (1). MRSA is one of the most 
common causes of nosocomial infections, especially inva-
sive bacterial infections (2), and is now endemic and even 
epidemic to many US hospitals, long-term care facilities (3), 
and communities (4–6). Although community-associated 
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MRSA (CA-MRSA) strains have been recognized as a lead-
ing cause of skin and soft tissue infections (1,6), especially in 
patients with no established healthcare risk factors (7,8), they 
also cause severe invasive infections (9,10). Recent reports 
based on genotypic evidence have suggested that CA-MRSA 
is likely spreading within hospitals as well, blurring the line 
between CA-MRSA and HA-MRSA infections (11).
Molecular typing studies have identiﬁ   ed 2 MRSA 
clones, USA300 and USA400, as the primary types that 
cause CA-MRSA infections (12). Evidence suggests that 
emergence of these strains was independent of hospital 
strains (13). Thus, understanding the role of outpatients, 
who are among the likely carriers of CA-MRSA into a 
hospital, is useful for understanding the changing epide-
miology of MRSA in hospitals. Outpatients, who outnum-
ber inpatients by ≈3:1, may play a major role in the spread 
of CA-MRSA strains from the community to the hospital 
through their interaction with hospital staff or use of similar 
hospital resources, such as surgical rooms. However, lim-
ited information hinders understanding of long-term trends 
in CA-MRSA in outpatients in the context of changing epi-
demiology of inpatients. This lack of information hinders 
the ability to evaluate infection control methods in the face 
of a possible emerging epidemic of nosocomial infections 
caused by CA-MRSA.
Knowledge of trends in antimicrobial drug resistance 
rates for emerging pathogens are useful to clinicians to en-
sure high-quality care, which is essential for antimicrobial 
drug therapy, in which different drugs can have different 
costs and effectiveness. These trends can also help hospital 
administrators and policy makers make infection control 
investments to address the role that large inﬂ  uxes of outpa-
tients with CA-MRSA infections may play with regard to 
overall MRSA infection rates in the hospital.
Methods
To analyze trends in frequency of CA-MRSA and HA-
MRSA, we studied changes in the proportion of isolates of 
each type that were found in inpatient and outpatient settings 
from a nationally representative sample of US hospitals dur-
ing 1999–2006. Although genotypic analysis is the most reli-
able way of identifying MRSA strains, historical genotypic 
data on isolates are not available at the national level. An al-
ternative approach is to ascertain strain type by using pheno-
typic susceptibility proﬁ  les. S. aureus susceptibility proﬁ  les 
are determined by the staphylococcal cassette chromosome 
(SCC) types on which the methicillin resistance gene, mecA, 
is carried. Because CA-MRSA and HA-MRSA strains typi-
cally have different SCCmec types, rules have been devel-
oped for determining the likely genetic makeup of an isolate 
on the basis of susceptibility results (11,14–16).
Phenotypic susceptibility results were obtained from 
The Surveillance Network (TSN) Database-USA (Focus 
Diagnostics, Herndon, VA, USA). TSN is an electronic 
repository of antimicrobial drug susceptibility data from a 
national network of >300 microbiology laboratories in the 
United States. Participating laboratories are geographically 
dispersed and make up a nationally representative sample 
based on patient population and number of beds. Patient 
isolates are tested on site as part of routine diagnostic test-
ing for susceptibility to different antimicrobial agents by 
using standards established by the Clinical and Laboratory 
Standards Institute (17) and approved by the US Food and 
Drug Administration. Results are then ﬁ  ltered to remove 
repeat isolates and identify microbiologically atypical re-
sults for conﬁ  rmation or veriﬁ  cation before being included 
in the TSN database. Data from the database have been 
used extensively to evaluate antimicrobial drug resistance 
patterns and trends (1,18–22).
Genotypic analysis of phenotypically deﬁ  ned strains 
has found that in general, isolates of the USA300 strain, 
the one most commonly associated with CA-MRSA infec-
tions, are resistant to fewer antimicrobial drugs (14–16). 
Naimi et al. (15) tested genetically determined CA-MRSA 
isolates against several antimicrobial drugs and found that 
they were typically susceptible to ciproﬂ  oxacin (79%) and 
clindamycin (83%). Similarly, King et al. (14) found that 
88% of CA-MRSA strains were resistant only to a β-lactam 
and erythromycin or a β-lactam only. Popovich et al. (16) 
also found that susceptibility to a ﬂ  uoroquinolone had a 
90% positive predictive value for predicting a community-
associated strain. Additionally, the number of antimicro-
bial drugs to which an isolate was susceptible was a reliable 
predictor of the genotype (16).
We analyzed S. aureus isolates that were tested for 
susceptibility to oxacillin (a proxy for all β-lactam anti-
microbial drugs). Isolates classiﬁ  ed as resistant according 
to Clinical and Laboratory Standards Institute breakpoint 
criteria were considered MRSA (<0.01% had intermedi-
ate resistance and were classiﬁ  ed as susceptible). MRSA 
isolates, regardless of source (outpatient or inpatient), that 
were tested against ciproﬂ  oxacin or clindamycin, and >3 
other drugs and found to be resistant only to oxacillin were 
classiﬁ  ed as CA-MRSA strains. Isolates resistant to oxa-
cillin and >1 other drug were assumed to be HA-MRSA 
strains. Other drugs tested were gentamicin, tetracycline, 
sulfamethoxazole/trimethoprim, and vancomycin.
Using this framework, we determined that the mean 
number of outpatient isolates analyzed annually was 
>50,000. Isolates were stratiﬁ  ed on the basis of source 
(blood, lungs, skin, and other organs). Conﬁ  dence inter-
vals (CIs) for TSN data were calculated by using the Wil-
son score method incorporating continuity correction as 
detailed by Newcombe (23). Statistical analysis was per-
formed by using Stata version 10 software (StataCorp LP, 
College Station, TX, USA).
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Results
Susceptibility to clindamycin, ciproﬂ  oxacin, gentami-
cin, tetracycline, sulfamethoxazole/trimethoprim, and van-
comycin was used to infer genotypes of MRSA isolates 
during 1999–2006. During this period, there was a statisti-
cally signiﬁ  cant reduction (p<0.001) in the proportion of 
MRSA isolates in outpatient areas resistant to ciproﬂ  oxa-
cin (84% to 56%), clindamycin (67% to 30%), gentamicin 
(30% to 3%), and sulfamethoxazole/trimethoprim (16% to 
2%). Our phenotypic rule, which was based on suscepti-
bility to all drugs, found qualitatively similar results, with 
the proportion of MRSA isolates resistant to >1 other drug 
decreasing from 87% to 46% during the period (Figure).
For outpatient data, the proportion of all S. aureus in-
fections that were MRSA infections nearly doubled, from 
26.8% (95% CI 26.3%–27.3%) to 52.4% (95% CI 52.0%–
52.9%), over the study period. This increase was caused 
almost entirely by increases in isolates resistant only to 
oxacillin, which increased >7× from 3.6% (95% CI 3.5%–
3.7%) to 28.2% (95% CI 28.0%–28.5%). The proportion of 
isolates resistant only to oxacillin increased for skin and soft 
tissue infections. However, increases were also observed 
in invasive blood and lung infections and other infections. 
Isolates resistant to >1 other drug increased ≈5% during 
1999–2001 from 23.2% (95% CI 23.0%–23.5%) to 28.2% 
(95% CI 28.0%–28.5%) before reaching a plateau. In 2005, 
the proportion of isolates resistant to oxacillin and 1 other 
drug then decreased back to almost the same percentage it 
started at. This pattern was driven by overall increases at all 
infection sites during 1999–2001 and later decreases at all 
collection sites except skin infections (Table).
Among inpatients, the proportion of S.  aureus iso-
lates that were MRSA increased 25% from 46.7% (95% CI 
46.2%–47.2%) to 58.5% (95% CI 58.0%–58.9%). Again, 
the increase was driven primarily by increases in the rate 
of isolates resistant only to oxacillin, which increased 
>7× from 3.3% (95% CI 3.1%–3.4%) to 19.8% (95% CI 
19.4%–20.1%). Similar to outpatient data, the frequency of 
skin and soft tissue infections increased for isolates resis-
tant only to oxacillin, although increases in blood, lung, and 
other infections were also observed. For isolates resistant to 
>1 other drug, a slightly different pattern was observed than 
for the pattern of outpatient isolate resistance. Instead of a 
large increase, the proportion of MRSA isolates resistant 
to >1 drug remained the same (≈43%–44%) until 2003 be-
fore decreasing >5% from 44.1% (95% CI 43.7%–44.5%) 
to 38.5% (95% CI 38.2%–38.9%) during 2003–2005. This 
decrease was largely caused by reductions in lung infec-
tions, although decreases were also seen in blood and other 
infections. Also different was the increase in MRSA skin 
isolates resistant to multiple drugs. There was an increase 
from 1999, but the increase was less (only 3%–4%) and ap-
peared to plateau at ≈12%–13%.
Discussion
We found during 1999–2006 that the percentage of S. 
aureus infections resistant to methicillin increased >90%, 
or ≈10% a year, in outpatients admitted to US hospitals. 
This increase was caused almost entirely by CA-MRSA 
strains, which increased >33% annually. Increases in the 
proportion of HA-MRSA isolates among outpatients were 
more variable, increasing ≈10% per year during 1999–2001 
before the increase slowed; the proportion then decreased 
over the second half of the study period. This reduction in 
the growth of HA-MRSA isolates corresponds to a steep 
increase in the frequency of CA-MRSA skin and soft tis-
sue infections among outpatients over an extremely short 
period, mostly during 2003–2005.
The frequency of CA-MRSA among inpatients in-
creased nearly in conjunction with outpatient rates, over-
all and at each infection site. However, increases in blood 
and lung infections increased more among inpatients than 
in outpatients, which likely reﬂ   ected the more severe 
status and increased likelihood of open wounds in inpa-
tients. During this same period, rates of HA-MRSA de-
creased only ≈10%. Most of this decrease occurred during 
2003–2005 and was mainly the result of a decrease in the 
frequency of HA-MRSA lung infections. This decrease 
was more likely the result of changes in empirical antimi-
crobial drug therapy for ventilator-associated pneumonia 
(24) than a consequence of any changes in the epidemiol-
ogy of MRSA.
Despite increases in the proportion of CA-MRSA 
strains among inpatients, the continuing high level of HA-
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Figure. Resistance of methicillin-resistant Staphylococcus 
aureus isolates to clindamycin, ciproﬂ   oxacin, gentamicin, and 
sulfamethoxazole/trimethoprim in outpatient areas of hospitals, 
United States, 1999–2006. Multiple drugs indicates isolates that 
were tested against ciproﬂ   oxacin or clindamycin and >3 other 
drugs and found to resistant only to oxacillin. The p values were 
calculated by using the χ2 test. Differences in all comparisons were 
signiﬁ  cant (p<0.001).RESEARCH
MRSA suggests that in contrast to reports from local insti-
tutions (11), CA-MRSA strains are adding to the problem 
of MRSA rather than replacing HA-MRSA strains. The fact 
that the frequency of HA-MRSA has decreased implies that 
some crowding out of HA-MRSA strains within the hospi-
tal may be occurring. However, lack of a decrease suggests 
that within the hospital, HA-MRSA strains may be more 
ﬁ  t, and thus CA-MRSA strains are unable to replace them 
fully. The result is a coexistence of both strains in the hos-
pital and maintenance of CA-MRSA because of the large 
inﬂ  ux of colonized and infected patients.
This ﬁ  nding is consistent with the biology of the 2 
strains, which suggests differential ﬁ  tness on the basis of 
the size of SCCmec. In CA-MRSA strains, the predominant 
SCCmec elements are types IV and V, which are small-
er than the SCCmec types typically found in HA-MRSA 
strains. These smaller genetic elements may increase the 
ﬁ  tness of CA-MRSA strains outside hospital-related anti-
microbial drug pressures, presumably by increasing mo-
bility and growth potential (25). However, their increased 
susceptibility to antibacterial agents in the hospital leaves 
them at a ﬁ  tness disadvantage. The result is that, although 
the community has effectively become a reservoir for the 
CA-MRSA strains that are continually introduced into the 
hospital population, without genetic changes, they are un-
likely to replace HA-MRSA strains in the hospital.
The large proportion of infections caused by CA-MR-
SA strains in hospitals with high frequencies of HA-MRSA 
has implications for drug-prescribing patterns within hos-
pitals. Because CA-MRSA strains are generally susceptible 
to more antimicrobial drugs, persons with these infections 
may be able to be treated with less expensive antimicrobial 
drugs with fewer adverse outcomes. Moreover, appropriate 
therapy can reduce the likelihood of emergence of other re-
sistant pathogens, such as vancomycin-resistant enterococ-
ci. Initial empiric therapy of infections with the suspected 
etiology of CA-MRSA must be tailored to antimicrobial 
drug susceptibility patterns within the local community and 
be based on efﬁ  cacy studies that suggest speciﬁ  c effective-
ness targets.
Kaplan suggested that empiric therapy should be mod-
iﬁ  ed if >10%–15% of CA-MRSA isolates become resistant 
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Table. Frequency of MRSA in hospitals, by unit, United States, 1999–2006* 
% Patients (95% confidence interval) 
Unit 1999 2000 2001 2002 2003 2004 2005 2006†
Outpatient
 All  MRSA  26.8
(26.3–27.3) 
29.4
(29.0–29.9) 
33.4
(33.0–33.9) 
35.7
(35.3–36.2) 
40.7
(40.2–41.2) 
47.7
(47.3–48.1) 
52.7
(52.3–53.1) 
52.4
(52.0–52.9) 
 HA-MRSA  23.2   
(23.0–23.5) 
25.1
(24.9–25.4) 
28.2
(28.0–28.5) 
28.4
(28.2–28.7) 
29.3
(29.0–29.5) 
28.4
(28.2–28.7) 
24.1
(23.8–24.3) 
24.2
(24.0–24.5) 
  Blood  2.7 2.8 4.0 3.7 3.1 2.8 2.1 1.9
  Lungs  4.7 5.3 6.5 5.5 5.4 4.2 3.5 2.9
  Skin  9.3 10.6 10.1 11.6 13.8 15.5 14.2 15.5
  Other  source  6.4 6.5 7.6 7.7 7.0 6.0 4.2 4.0
 CA-MRSA  3.6   
(3.5–3.7) 
4.3
(4.2–4.4) 
5.2
(5.1–5.4) 
7.3
(7.1–7.5) 
11.4
(11.3–11.6) 
19.3
(19.1–19.5) 
28.7
(28.4–28.9) 
28.2
(28.0–28.5) 
  Blood  0.3 0.3 0.6 0.7 0.8 0.8 0.9 0.8
  Lungs  0.4 0.5 0.9 0.9 0.7 0.6 0.8 0.7
  Skin  2.3 3.0 2.9 4.8 9.0 16.6 25.3 25.4
  Other  source  0.5 0.5 0.8 0.9 1.0 1.3 1.6 1.4
Inpatient
 All  MRSA  46.7
(46.2–47.2) 
47.6
(47.2–48.1) 
50.0
(49.6–50.4) 
52.2
(51.8–52.6) 
54.9
(54.6–55.3) 
58.3
(57.9–58.6) 
59.5
(59.2–59.9) 
58.5
(58.0–58.9) 
 HA-MRSA  43.4   
(43.0–43.9) 
43.2
(42.8–43.6) 
44.1
(43.7–44.5) 
43.9
(43.5–44.3) 
44.1
(43.7–44.5) 
41.9
(41.6–42.3) 
38.5
(38.2–38.9) 
38.7
(38.3–39.1) 
  Blood  7.1 7.2 7.5 7.5 7.5 7.0 6.2 6.3
  Lungs  21.4 19.9 19.2 18.5 17.6 16.5 14.7 14.5
  Skin  9.3 10.5 11.4 12.0 12.9 13.1 13.0 13.1
  Other  source  5.6 5.6 6.0 5.9 6.1 5.3 4.5 4.7
 CA-MRSA  3.3   
(3.1–3.4) 
4.5
(4.3–4.6) 
5.8
(5.6–6.0) 
8.4
(8.2–8.6) 
10.9
(10.6–11.1) 
16.3
(16.1–16.6) 
21.0
(20.7–21.3) 
19.8
(19.4–20.1) 
  Blood  0.6 0.7 1.0 1.2 1.2 1.7 2.1 2.0
  Lungs  1.2 1.6 2.1 2.3 2.1 2.6 3.3 3.8
  Skin  1.1 1.7 2.1 4.0 6.6 10.9 14.4 12.8
  Other  source  0.4 0.5 0.7 0.9 1.0 1.2 1.3 1.2
*MRSA, methicillin-resistant Staphylococcus aureus; HA-MRSA, hospital-associated MRSA; CA-MRSA, community-associated MRSA. 
†Data through October only. Data for blood, lungs, skin, and other source refer to the percentage of each source tested that was estimated to be CA-
MRSA or HA-MRSA.  CA-MRSA in Outpatients, United States, 1999–2006
to a speciﬁ  c empiric therapy (26). Conversely, it may be 
appropriate to reintroduce a speciﬁ  c agent when suscepti-
bility levels increase above a threshold. However, cycling 
strategies may not always be optimal (27), and no efﬁ  cacy 
studies have been conducted to establish this target. In ad-
dition, we urge caution in applying national results to the 
CA-MRSA antibiogram of a speciﬁ  c area. Although results 
showed an overall trend at the national level, speciﬁ  c re-
sults at individual testing centers tended to be more vari-
able. Moreover, local health ofﬁ  cials and hospitals should 
coordinate their efforts to identify susceptibility patterns at 
the community level, rather than at the hospital level, to 
optimize the gains from investments in infection control 
(28).
The results of our study should be interpreted with cau-
tion because TSN provides information concerning only the 
site of isolate collection and not the infection. In addition, 
TSN only provides information on the collection location 
(i.e., outpatient or inpatient) and not case histories. Thus, 
some isolates may be difﬁ  cult to classify in situations such 
as when an isolate was collected in the emergency depart-
ment and then the patient was admitted or the patient was 
discharged and then returned as an outpatient. However, 
the effect of these situations is likely to be small because 
most isolates are from patients who can be classiﬁ  ed as in-
patients or outpatients.
A further limitation of the study is that although CA-
MRSA isolate drug susceptibility patterns are technically 
genetically determined, the data enabled only phenotypic 
classiﬁ  cation of isolates. In addition, as with any large 
time-series database, changes in surveillance or bias in the 
types of infections cultured over time, such as more severe 
or unusual infections, could alter the results. These ﬁ  ndings 
suggest that more complicated bacteriology could alter the 
results. However, no general trend in the number of isolates 
collected was seen at individual testing centers, and resis-
tance results from the TSN database were comparable to 
results of other national studies (1). Furthermore, the strik-
ing increases over the study period suggest that the trends 
are likely robust to any bias.
In summary, we examined the frequency of CA-MR-
SA and HA-MRSA in inpatient and outpatient settings. Our 
results indicate that outpatients may be a major reservoir of 
CA-MRSA, which will continue to enter hospitals, exac-
erbating the problem of MRSA. However, although CA-
MRSA isolates have undoubtedly spread within hospitals 
and are likely to continue to do so, without changes in the 
ﬁ  tness of different strains, CA-MRSA strains are unlikely 
to displace HA-MRSA strains within the hospital.
Our ﬁ  ndings have implications for local and national 
policies aimed at containing and preventing MRSA. More 
rapid diagnostic methods are urgently needed to better aid 
physicians in determining appropriate empiric therapy. 
Strategies for prevention of infection and treatment of pa-
tients with CA-MRSA within healthcare settings should be 
coordinated primarily at the local level in accordance with 
local susceptibility proﬁ  les. Lastly, infection control poli-
cies should take into account the role that outpatients likely 
play in the spread of MRSA and promote interventions that 
could prevent spread of MRSA from outpatient areas to in-
patient areas.
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